AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7951339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing retroperitoneal lymph-node dissection (RPLND)
Number of subjects: 0
Study 3582135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg b.d. for 5 days
Number of subjects: 385
Study 3582135 — intervention group
Group type: COMPARATOR
Intervention: Augmentin 375 mg t.d.s. for 5 days
Number of subjects: 385
Study 3582135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 385
Study 3582135 — intervention group
Group type: COMPARATOR
Intervention: Augmentin
Number of subjects: 385
Study 31087564 — intervention group
Group type: COMPARATOR
Intervention: Eribulin mesylate (EM) in third line
Number of subjects: 16703
Study 31087564 — intervention group
Group type: COMPARATOR
Intervention: Eribulin mesylate (EM) in fourth line
Number of subjects: 16703
Study 31087564 — intervention group
Group type: COMPARATOR
Intervention: Eribulin mesylate (EM) in second line
Number of subjects: 16703
Study 31087564 — intervention group
Group type: COMPARATOR
Intervention: Eribulin mesylate (EM) in second line among HER2- patients
Number of subjects: 16703
Study 28289237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (clopidogrel-aspirin)
Number of subjects: 2933
Study 28289237 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2933
Study 26411504 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS) containing 90 µg I with 0 or 10 mg Zn, 20 g/day from 9 to 18 months of age.
Number of subjects: 179
Study 26411504 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention cohort) received no SQ-LNS.
Number of subjects: 179
Study 24261022 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-interferon (peg-IFN) plus ribavirin (RBV)
Number of subjects: 154
Study 21410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally dosed non-(14)C-labeled lesogaberan (100 mg)
Number of subjects: 10
Study 21410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously infused non-(14)C-labeled lesogaberan (20 mg)
Number of subjects: 10
Study 21410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered (14)C-labeled lesogaberan (100 mg)
Number of subjects: 10
Study 21410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered (14)C-labeled lesogaberan (20 mg)
Number of subjects: 10
Study 18285436 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation method using surrogate endpoint in new trial
Number of subjects: 20
Study 18285436 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesis testing method using z-statistic for surrogate endpoint
Number of subjects: 20
Study 16448895 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 to 100 mg
Number of subjects: 59
Study 16448895 — intervention group
Group type: COMPARATOR
Intervention: candesartan 8 to 16 mg
Number of subjects: 59
Study 16448895 — intervention group
Group type: EXPERIMENTAL
Intervention: both losartan and candesartan
Number of subjects: 59
Study 12562705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets 250/125 mg
Number of subjects: 144
Study 12562705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets 500/125 mg
Number of subjects: 144
Study 12562705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets 875/125 mg
Number of subjects: 144
Study 12562705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral suspension 250/62.5 mg per 5 mL
Number of subjects: 144
Study 11524325 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine injection
Number of subjects: 21
Study 11524325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epidural morphine)
Number of subjects: 21
Study 9674185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB)
Number of subjects: 39
Study 9674185 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (BEC)
Number of subjects: 39
Study 8513309 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg o.d. (doubled after 1 month if seated diastolic BP was > or = 95 mmHg)
Number of subjects: 26
Study 8513309 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-Canrenoate (K-Can) 50 mg o.d. (doubled after 1 month if seated diastolic BP was > or = 95 mmHg)
Number of subjects: 26
Study 8513309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (HCTZ and K-Can)
Number of subjects: 26
Study 2872804 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 40 mg once daily)
Number of subjects: 351
Study 2872804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 31407323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31407323 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methodological procedures in PCRPS
Number of subjects: 0
Study 28926353 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide 200 mg
Number of subjects: 38
Study 28926353 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide 800 mg
Number of subjects: 38
Study 28926353 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5 mg
Number of subjects: 38
Study 28926353 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 3 mg
Number of subjects: 38
Study 25376971 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus Pecs block (Pecs group, n = 60)
Number of subjects: 120
Study 25376971 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (control group, n = 60)
Number of subjects: 120
Study 25474391 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-focused care (FFC) for assisted living intervention (FFC-AL)
Number of subjects: 171
Study 21072736 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and strength training for 8 weeks at the worksite
Number of subjects: 32
Study 21072736 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after 8 weeks of training
Number of subjects: 32
Study 21072736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 19117563 — intervention group
Group type: EXPERIMENTAL
Intervention: Two layers of cotton underpadding
Number of subjects: 45
Study 19117563 — intervention group
Group type: EXPERIMENTAL
Intervention: Four layers of cotton underpadding
Number of subjects: 45
Study 19117563 — intervention group
Group type: COMPARATOR
Intervention: Both cast designs
Number of subjects: 45
Study 17120972 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose Vi polysaccharide vaccine (Typherix)
Number of subjects: 32267
Study 17120972 — intervention group
Group type: COMPARATOR
Intervention: Active control hepatitis A vaccine (Havrix)
Number of subjects: 32267
Study 15257908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration with AN69 membrane (adsorption group)
Number of subjects: 30
Study 15257908 — intervention group
Group type: COMPARATOR
Intervention: Ultrafiltration with polysulfone (PS) membrane (control group)
Number of subjects: 30
Study 11275505 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice methadone maintenance treatment
Number of subjects: 125
Study 11275505 — intervention group
Group type: COMPARATOR
Intervention: Drug clinic methadone maintenance treatment
Number of subjects: 125
Study 9284777 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH [1-34], 400 U/25 micrograms daily subcutaneously
Number of subjects: 34
Study 9284777 — intervention group
Group type: COMPARATOR
Intervention: Hormone-replacement therapy only (Control)
Number of subjects: 34
Study 8392359 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural bupivacaine
Number of subjects: 40
Study 8392359 — intervention group
Group type: COMPARATOR
Intervention: Systemic opioids
Number of subjects: 40
Study 8392359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (Extradural bupivacaine and Systemic opioids)
Number of subjects: 40
Study 2437455 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide with cisplatin and bleomycin
Number of subjects: 261
Study 2437455 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine with cisplatin and bleomycin
Number of subjects: 261
Study 2437455 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide with cisplatin and bleomycin (high tumor volume)
Number of subjects: 261
Study 2437455 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine with cisplatin and bleomycin (high tumor volume)
Number of subjects: 261
Study 29131664 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotomy performed on the test side
Number of subjects: 8
Study 29131664 — intervention group
Group type: COMPARATOR
Intervention: Control side (noncorticotomized)
Number of subjects: 8
Study 27511844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetux‐FHX (cetuximab, 5‐fluorouracil, hydroxyurea, and 1.5 Gy twice‐daily radiation therapy every other week to 75 Gy)
Number of subjects: 110
Study 27511844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetux‐PX (cetuximab, cisplatin, and accelerated radiation therapy with delayed concomitant boost to 72 Gy in 42 fractions)
Number of subjects: 110
Study 27511844 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 110
Study 27511844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetux‐FHX
Number of subjects: 110
Study 27511844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetux‐PX
Number of subjects: 110
Study 27511844 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 110
Study 27511844 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive patients
Number of subjects: 110
Study 27511844 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative patients
Number of subjects: 110
Study 23736964 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-targeted patient navigation (PN)
Number of subjects: 392
Study 23736964 — intervention group
Group type: COMPARATOR
Intervention: Standard patient navigation (PN)
Number of subjects: 392
Study 23067912 — intervention group
Group type: EXPERIMENTAL
Intervention: System delay 0 to 120 minutes
Number of subjects: 219
Study 23067912 — intervention group
Group type: EXPERIMENTAL
Intervention: System delay 121 to 180 minutes
Number of subjects: 219
Study 23067912 — intervention group
Group type: EXPERIMENTAL
Intervention: System delay >180 minutes
Number of subjects: 219
Study 20735366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood management intervention (integration of control intervention with a mood management component including a self-help manual, two additional proactive telephone sessions, and homework assignments)
Number of subjects: 485
Study 20735366 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (eight sessions of proactive telephone counselling)
Number of subjects: 485
Study 20735366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood management intervention
Number of subjects: 485
Study 17226852 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy in children with heterozygous CYP2C9 polymorphisms
Number of subjects: 29
Study 17226852 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy in children on concomitant corticosteroids
Number of subjects: 29
Study 16114787 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 20,000 U every two weeks (Q2W)
Number of subjects: 519
Study 16114787 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 30,000 U every three weeks (Q3W)
Number of subjects: 519
Study 16114787 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 U every four weeks (Q4W)
Number of subjects: 519
Study 16114787 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 10,000 U once weekly (QW)
Number of subjects: 519
Study 16114787 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment across all dosing groups
Number of subjects: 519
Study 16114787 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluation of epoetin alfa
Number of subjects: 519
Study 12134227 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 33
Study 10405232 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy using omeprazole (30 mg twice a day) plus clarithromycin (500 mg twice a day) and amoxicillin (1 g twice a day)
Number of subjects: 143
Study 10405232 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy using lansoprazole (30 mg twice a day) plus clarithromycin (500 mg twice a day) and amoxicillin (1 g twice a day)
Number of subjects: 143
Study 10405232 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy using omeprazole or lansoprazole plus clarithromycin and amoxicillin
Number of subjects: 143
Study 7562290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose
Number of subjects: 0
Study 7562290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-glucose polymer combination
Number of subjects: 0
Study 7562290 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymers alone
Number of subjects: 0
Study 7562290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-glucose polymer combination and glucose polymers alone
Number of subjects: 0
Study 1536959 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (8 micrograms glycoprotein (5.5 micrograms protein)/kg/d, continuous IV infusion for 14 days)
Number of subjects: 57
Study 1536959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 6509876 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt phenytoin sodium capsules (divided doses)
Number of subjects: 5
Study 6509876 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt phenytoin sodium capsules (single doses)
Number of subjects: 5
Study 6509876 — intervention group
Group type: COMPARATOR
Intervention: Extended phenytoin sodium capsules
Number of subjects: 5
Study 6509876 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin sodium injection
Number of subjects: 5
Study 31891298 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 2-stage inferior alveolar nerve block (IANB)
Number of subjects: 64
Study 31891298 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2-stage inferior alveolar nerve block (IANB)
Number of subjects: 64
Study 30311896 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 grams IV 24 hours preoperatively, 500 mg every 12 hours IV for 48 hours in ICU, and 500 mg every 12 hours PO for 48 hours in ward)
Number of subjects: 314
Study 30311896 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin C)
Number of subjects: 314
Study 30311896 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 314
Study 30311896 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 314
Study 24361097 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer test with anesthesia
Number of subjects: 20
Study 24361097 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer test without anesthesia
Number of subjects: 20
Study 24361097 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior gaze position
Number of subjects: 20
Study 24361097 — intervention group
Group type: COMPARATOR
Intervention: Palpebral aperture, age, and OSDI questionnaire
Number of subjects: 20
Study 22337646 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse-assisted coping skills training protocol for patients undergoing a multidisciplinary pain management programme (SA-MPMP)
Number of subjects: 36
Study 22337646 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient-oriented multidisciplinary pain management programme (P-MPMP)
Number of subjects: 36
Study 22337646 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 36
Study 19575366 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 microg/kg peginterferon alfa-2b weekly plus 800-1,400 mg ribavirin daily for 48 weeks (group A)
Number of subjects: 433
Study 19575366 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored treatment duration (18-48 weeks; group B)
Number of subjects: 433
Study 17855692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-fruit and -vegetable diet
Number of subjects: 801
Study 17855692 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 801
Study 15073109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 1 mg daily
Number of subjects: 120
Study 15073109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg daily
Number of subjects: 120
Study 15073109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 120
Study 15073109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (all doses)
Number of subjects: 120
Study 11199932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg starting dose for 12 weeks or 25 mg starting dose for 10 weeks)
Number of subjects: 705
Study 11199932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 705
Study 11199932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 11199932 — intervention group
Group type: COMPARATOR
Intervention: Sertraline and Placebo
Number of subjects: 705
Study 9753259 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every morning
Number of subjects: 472
Study 9753259 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 472
Study 8172800 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF regimen (A)
Number of subjects: 40
Study 8172800 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ELF regimen (B)
Number of subjects: 40
Study 3065016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of human zinc insulin (Monotard HM) with soluble human insulin (Actrapid HM)
Number of subjects: 8
Study 3065016 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of human zinc insulin (Monotard HM) with soluble human insulin (Actrapid HM)
Number of subjects: 8
Study 3065016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of protamine insulin (Protaphan HM) with soluble human insulin (Actrapid HM)
Number of subjects: 8
Study 3065016 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of protamine insulin (Protaphan HM) with soluble human insulin (Actrapid HM)
Number of subjects: 8
Study 30148731 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits and HIV testing information (study arm 3)
Number of subjects: 1410
Study 30148731 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care and a standard information card (study arm 1)
Number of subjects: 1410
Study 30148731 — intervention group
Group type: COMPARATOR
Intervention: Improved card stating the importance of male HIV testing (study arm 2)
Number of subjects: 1410
Study 30148731 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits
Number of subjects: 1410
Study 27002770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to interpersonal violence in the home
Number of subjects: 989
Study 27002770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to community violence
Number of subjects: 989
Study 27002770 — intervention group
Group type: EXPERIMENTAL
Intervention: Harsh physical discipline
Number of subjects: 989
Study 27002770 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to home and community violence
Number of subjects: 989
Study 27002770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing participation in the community-based programme
Number of subjects: 989
Study 24726205 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Ts score of 3 or lower (low pretest probability of HIT)
Number of subjects: 794
Study 24726205 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Ts score of 4-5 (moderate pretest probability of HIT)
Number of subjects: 794
Study 24726205 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Ts score of ≥6 (high pretest probability of HIT)
Number of subjects: 794
Study 24726205 — intervention group
Group type: COMPARATOR
Intervention: Agreement between research coordinators and central adjudication
Number of subjects: 794
Study 22897985 — intervention group
Group type: EXPERIMENTAL
Intervention: Local topical anesthesia (LT) with 5% lidocaine and 5% prilocaine cream
Number of subjects: 41
Study 22897985 — intervention group
Group type: COMPARATOR
Intervention: Dorsal penile nerve block (DPNB) with 0.5% bupivacaine (1 mg/kg)
Number of subjects: 41
Study 19484485 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-stretch compressive bandaging
Number of subjects: 61
Study 19484485 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate semi-rigid bandage
Number of subjects: 61
Study 17961161 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1-negative tumors
Number of subjects: 159
Study 17961161 — intervention group
Group type: COMPARATOR
Intervention: ERCC1-positive tumors
Number of subjects: 159
Study 17961161 — intervention group
Group type: EXPERIMENTAL
Intervention: T/T genotype
Number of subjects: 159
Study 16428249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for two weeks
Number of subjects: 1558
Study 16428249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study 14636765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% povidone iodine subeschar clysis (PVP‐SEC) in addition to surface application of povidone iodine + Neosporin
Number of subjects: 613
Study 14636765 — intervention group
Group type: COMPARATOR
Intervention: Crust application only (control group)
Number of subjects: 613
Study 10688395 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone + glyburide
Number of subjects: 1000
Study 10688395 — intervention group
Group type: COMPARATOR
Intervention: Glyburide alone
Number of subjects: 1000
Study 9678123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose monophasic combined oral contraceptive (100 micrograms levonorgestrel/20 micrograms ethinylestradiol)
Number of subjects: 15
Study 1337160 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo) at target Hb 9 g/dl
Number of subjects: 12
Study 3986113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lignocaine
Number of subjects: 52
Study 3986113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lignocaine without diazepam
Number of subjects: 52